Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review
Susan J. F. van Maren, Eveline P. M. van Doorn, Mark M. Smits, Cees J. J. Tack, Elisabeth F. C. van Rossum, Saloua El Messaoudi · 2026
Read Effects of GLP-1 receptor agonists on body weight and cardiovascular outcomes: a review by Susan J. F. van Maren, Eveline P. M. van Doorn, Mark M. Smits, Cees J. J. Tack, Elisabeth F. C. van Rossum, Saloua El Messaoudi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615203.txt.
Description
Susan van Maren and co-authors review a drug class that cuts weight and protects the heart in a 2026 paper. The drugs mimic a gut hormone called GLP-1 and were first built for diabetes. Obesity keeps rising worldwide, and lifestyle programs alone seldom hold weight off for good.
Across large outcome trials, these drugs lowered heart attacks, deaths, and heart failure admissions in people with diabetes. In people with obesity but no diabetes, one drug cut cardiovascular events in a landmark trial, partly beyond what weight loss explains. The drugs also calm inflammation and improve blood vessel function. The authors argue they belong in mainstream cardiovascular prevention for high-risk patients, and they map where the class fits in care.
Catalog record
| CREATOR | Susan J. F. van Maren, Eveline P. M. van Doorn, Mark M. Smits, Cees J. J. Tack, Elisabeth F. C. van Rossum, Saloua El Messaoudi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |